GeneReach Biotechnology (4171) — Cash Flow Quality Index
GeneReach Biotechnology (4171) has a Cash Flow Quality Index of 4.33x as of December 2025. Operating cash flow of NT$12.05 Million exceeds net income of NT$2.79 Million, indicating high earnings quality where cash backs reported profits. Explore 4171 operating cash flow to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
GeneReach Biotechnology Cash Flow Quality Index (2018–2022)
Historical Cash Flow Quality Index for GeneReach Biotechnology across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check how aggressively does GeneReach Biotechnology reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for GeneReach Biotechnology (2018–2022)
Year-by-year earnings quality comparison for GeneReach Biotechnology. For live market cap and the full company financial profile, see how much is GeneReach Biotechnology worth.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2022 | 1.62x | NT$357.63 Million | NT$221.34 Million | ▲ +117.3% |
| 2021 | 0.74x | NT$348.99 Million | NT$469.37 Million | ▲ +48.4% |
| 2020 | 0.50x | NT$169.82 Million | NT$338.94 Million | ▲ +445.5% |
| 2019 | -0.15x | NT$-11.19 Million | NT$77.18 Million | ▼ -172.1% |
| 2018 | 0.20x | NT$5.74 Million | NT$28.57 Million | — |